ZIOPHARM Oncology Inc (ZIOP)

2.28 -0.11  -4.60% NASDAQ Apr 3, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/08/2020 16:30 EDT Misc ZIOPHARM Oncology Inc First Quarter Earnings Conference Call in 2020
05/08/2020 Earnings ZIOPHARM Oncology Inc First Quarter Earnings in 2020 Release
03/02/2020 16:30 EST Misc ZIOPHARM Oncology Inc Fourth Quarter Earnings Conference Call for 2019
03/02/2020 Earnings ZIOPHARM Oncology Inc Fourth Quarter Earnings in 2019 Release
03/02/2020 Misc ZIOPHARM Oncology Inc Annual Report for 2019
11/07/2019 16:30 EST Misc ZIOPHARM Oncology Inc Third Quarter Earnings Conference Call for 2019
11/07/2019 Earnings ZIOPHARM Oncology Inc Third Quarter Earnings in 2019 Release
08/08/2019 Earnings ZIOPHARM Oncology Inc Second Quarter Earnings in 2019 Release
08/08/2019 08:30 EDT Misc ZIOPHARM Oncology Inc Second Quarter Earnings Conference Call in 2019
06/13/2019 10:00 EDT Misc ZIOPHARM Oncology Inc Annual General Meeting in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.ziopharm.com
  • Investor Relations URL: http://ir.ziopharm.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: May. 08, 2020
  • Last Earnings Release: Mar. 02, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad.

Top Fund Holders

Symbol Name Weighting
MVISX Miller Opportunity IS 2.65%
CNCR Loncar Cancer Immunotherapy ETF 2.20%
VALX Validea Market Legends ETF 1.76%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.